PregnanTech
Preterm Birth Prevention
Company Overview
Snapshot
Founded in January 2017 by David Shashar and Avi Tsur, PregnanTech operates with 1–10 employees. The company has secured funding across 4 disclosed rounds from 5 investors. In January 2026, PregnanTech received an investment from Longliv Ventures.
Business overview
PregnanTech is a Health Tech & Life Sciences company focused on developing solutions to prevent preterm birth. Its core product, the Lioness, is a small, disposable device designed to maintain the natural resistance of the cervix. The device functions as a shock absorber, allowing transient cervical shortening and dilation during contractions before restoring the cervix to its initial state. PregnanTech serves the healthcare industry, specifically targeting gynecology and women's health within hospitals and clinics.
Strategic signal
In July 2024, PregnanTech was highlighted in a PR Newswire release regarding its efforts to confront the preterm birth crisis. This signals continued validation of the company's mission and the potential impact of its Lioness device in addressing a critical medical challenge, indicating ongoing strategic momentum and relevance within the women's health sector.
Company Intelligence Q&A
- What is PregnanTech's primary focus?
- PregnanTech is focused on developing medical devices to prevent preterm birth, with its flagship product being the Lioness device.
- When was PregnanTech founded and by whom?
- PregnanTech was founded in January 2017 by David Shashar and Avi Tsur.
- What is the Lioness device?
- The Lioness is a small, disposable device developed by PregnanTech designed to maintain the natural resistance of the cervix to prevent preterm birth. It acts like a shock absorber, allowing temporary cervical changes during contractions and then restoring its original state.
- Has PregnanTech received recent funding?
- This marks one of four disclosed funding rounds for the company.
- What significant clinical progress has PregnanTech made?
- PregnanTech has conducted successful preclinical studies and, in 2019, began a clinical safety study of the Lioness device among non-pregnant women. Initial findings have demonstrated significant potential.